KPV vs LL-37.

KPV is a synthetic tripeptide composed of L-lysine, L-proline, and L-valine (Lys-Pro-Val), corresponding to the C-terminal residues 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH). It is the smallest fragment of alpha-MSH that retains the parent hormone's anti-inflammatory activity, and it is studied as a melanocortin-derived anti-inflammatory agent that lacks the pigmentary (melanogenic) action of the full hormone. It is a research compound, not an approved drug.

LL-37 is the only human cathelicidin-derived antimicrobial peptide, a 37-residue cationic, amphipathic alpha-helical peptide (named for its two leading leucine residues) cleaved from the C-terminus of the precursor protein hCAP18 (gene CAMP). It is an endogenous component of innate immunity, produced by neutrophils, epithelial cells, keratinocytes, and other tissues, where it acts as both a broad-spectrum antimicrobial and a host-defense signaling molecule.

KPV's anti-inflammatory action appears to be largely receptor-independent: rather than signaling primarily through classical melanocortin receptors, it is taken up into intestinal epithelial and immune cells by the proton-coupled di/tripeptide transporter PepT1 (SLC15A1), which is normally restricted to the small intestine but is induced in the colon during inflammation. Once intracellular, KPV dampens canonical pro-inflammatory signaling, notably inhibiting NF-kB and MAP-kinase pathway activation and reducing secretion of pro-inflammatory cytokines. Work dissecting alpha-MSH fragments also implicates antagonism of IL-1beta-driven inflammatory functions as a contributor to its effect. This combination of mechanisms is the basis for its preclinical study in mucosal inflammation.

As a cationic amphipathic peptide, LL-37 binds anionic microbial membranes and disrupts them (a detergent-like/toroidal-pore mechanism), giving broad activity against Gram-positive and Gram-negative bacteria, some fungi, and enveloped viruses, plus the ability to neutralize LPS and disrupt biofilms. Beyond direct killing, it is strongly immunomodulatory: it is chemotactic for neutrophils, monocytes, and T cells (acting partly via the FPR2/FPRL1 receptor), promotes angiogenesis and keratinocyte migration and proliferation (relevant to wound re-epithelialization), and modulates Toll-like-receptor and inflammatory signaling. A double-edged feature is that LL-37 can bind self-DNA/RNA and convert it into a potent activator of plasmacytoid dendritic cells via TLR9/TLR7, a pathway implicated in psoriasis and other autoimmunity.

The evidence base for KPV is preclinical (cell culture and rodent models); there are no completed human clinical trials demonstrating efficacy or safety. Dalmasso and colleagues (Gastroenterology, 2008) showed that nanomolar KPV inhibited NF-kB and MAP-kinase activation in human intestinal epithelial (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells via PepT1, and that oral KPV reduced DSS- and TNBS-induced colitis in mice. Kannengiesser et al. (Inflammatory Bowel Diseases, 2008) reported that KPV attenuated disease in DSS and CD45RB-transfer murine colitis models, with effects that did not require functional MC1R, supporting a non-melanocortin-receptor mechanism. Earlier mechanistic dissection by Getting, Schioth, and Perretti (J Pharmacol Exp Ther, 2003) compared core and C-terminal (KPV) alpha-MSH peptides and characterized their anti-inflammatory pharmacology. The broader pharmacology is summarized in a review by Brzoska et al. (Endocrine Reviews, 2008); the gap to human disease remains unbridged.

Direct human interventional evidence is limited and centers on chronic wounds. A multicentric, prospective, randomized, placebo-controlled trial evaluated topical LL-37 in hard-to-heal venous leg ulcers (Gronberg et al., Wound Repair Regen, 2021, PMID 34687253), building on an earlier safety/efficacy study reporting improved healing of venous leg ulcers (PMID 25041740); these are small, wound-specific studies rather than large confirmatory trials. The great majority of the LL-37 literature is mechanistic, in vitro, or animal-based: for example, cathelicidin's protective role against urinary-tract infection was shown in mice and human cells (Chromek et al., Nat Med, 2006, PMID 16751768). Much of the peptide's purported breadth (antiviral, anticancer, antibiofilm, metabolic effects) remains preclinical, and endogenous LL-37 biology should not be conflated with proven benefit from administering exogenous LL-37 in humans. Honest summary: human efficacy data exist mainly for topical chronic-wound healing and remain early-stage; systemic therapeutic use is not established.

Documented safety data come almost entirely from cell and rodent studies, where KPV has generally been reported as well tolerated at the doses tested; there is no established human safety profile, no characterized adverse-event spectrum in people, and no pharmacovigilance data. Long-term effects, immunogenicity, effects in pregnancy, and drug interactions are unknown. Because PepT1 expression and KPV uptake are upregulated specifically in inflamed tissue, the cellular pharmacology may differ between healthy and diseased states, which is not characterized in humans. Material sold for research or compounded use is not subject to pharmaceutical-grade quality control, introducing additional purity and identity risks.

LL-37 has a genuinely double-edged profile: the same self-nucleic-acid-binding and dendritic-cell-activating activity that aids host defense is mechanistically implicated in autoimmune and inflammatory disease, and LL-37 is recognized as an autoantigen targeted by T cells in psoriasis. Elevated or dysregulated cathelicidin has also been linked to rosacea, lupus, atherosclerosis, and a context-dependent (pro- or anti-) role in cancer, so effects are highly tissue- and concentration-dependent. At higher concentrations the peptide can be cytotoxic and hemolytic to host cells, and it can be degraded or inactivated by serum and proteases, complicating systemic delivery. Human safety data are essentially confined to localized topical wound use; the safety of exogenous systemic administration in humans is not established.

KPV is not approved by the FDA (or other major regulators) for any indication and has no marketed drug product; it is an investigational/research-use compound. It is not a recognized dietary supplement ingredient, and any human use occurs outside of established regulatory approval.

LL-37 is not an FDA-approved drug; it is an endogenous human peptide studied as an investigational and research-use agent. Clinical work has been early-phase and indication-specific (notably topical chronic-wound trials), and no LL-37 product holds general marketing approval.